Cigarette Smoke Induces C/EBP-β-Mediated Activation of miR-31 in Normal Human Respiratory Epithelia and Lung Cancer Cells by Xi, Sichuan et al.
Cigarette Smoke Induces C/EBP-b-Mediated Activation of
miR-31 in Normal Human Respiratory Epithelia and Lung
Cancer Cells
Sichuan Xi
1, Maocheng Yang
1, Yongguang Tao
2, Hong Xu
2, Jigui Shan
3, Suzanne Inchauste
1,M a r y
Zhang
1, Leandro Mercedes
1, Julie A. Hong
1, Mahadev Rao
1, David S. Schrump
1*
1Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America, 2Laboratory of Cancer
Prevention, National Cancer Institute, Frederick, Maryland, United States of America, 3Advanced Biomedical Computing Center, SAIC-Frederick, National Cancer Institute,
Frederick, Maryland, United States of America
Abstract
Background: Limited information is available regarding mechanisms by which miRNAs contribute to pulmonary
carcinogenesis. The present study was undertaken to examine expression and function of miRNAs induced by cigarette
smoke condensate (CSC) in normal human respiratory epithelia and lung cancer cells.
Methodology: Micro-array and quantitative RT-PCR (qRT-PCR) techniques were used to assess miRNA and host gene
expression in cultured cells, and surgical specimens. Software-guided analysis, RNA cross-link immunoprecipitation (CLIP), 39
UTR luciferase reporter assays, qRT-PCR, focused super-arrays and western blot techniques were used to identify and
confirm targets of miR-31. Chromatin immunoprecipitation (ChIP) techniques were used to evaluate histone marks and
transcription factors within the LOC554202 promoter. Cell count and xenograft experiments were used to assess effects of
miR-31 on proliferation and tumorigenicity of lung cancer cells.
Results: CSC significantly increased miR-31 expression and activated LOC554202 in normal respiratory epithelia and lung
cancer cells; miR-31 and LOC554202 expression persisted following discontinuation of CSC exposure. miR-31 and
LOC554202 expression levels were significantly elevated in lung cancer specimens relative to adjacent normal lung tissues.
CLIP and reporter assays demonstrated direct interaction of miR-31 with Dickkopf-1 (Dkk-1) and DACT-3. Over-expression of
miR-31 markedly diminished Dkk-1 and DACT3 expression levels in normal respiratory epithelia and lung cancer cells.
Knock-down of miR-31 increased Dkk-1 and DACT3 levels, and abrogated CSC-mediated decreases in Dkk-1 and DACT-3
expression. Furthermore, over-expression of miR-31 diminished SFRP1, SFRP4, and WIF-1, and increased Wnt-5a expression.
CSC increased H3K4Me3, H3K9/14Ac and C/EBP-b levels within the LOC554202 promoter. Knock-down of C/EBP-b
abrogated CSC-mediated activation of LOC554202. Over-expression of miR-31 significantly enhanced proliferation and
tumorigenicity of lung cancer cells; knock-down of miR-31 inhibited growth of these cells.
Conclusions: Cigarette smoke induces expression of miR-31 targeting several antagonists of cancer stem cell signaling in
normal respiratory epithelia and lung cancer cells. miR-31 functions as an oncomir during human pulmonary carcinogenesis.
Citation: Xi S, Yang M, Tao Y, Xu H, Shan J, et al. (2010) Cigarette Smoke Induces C/EBP-b-Mediated Activation of miR-31 in Normal Human Respiratory Epithelia
and Lung Cancer Cells. PLoS ONE 5(10): e13764. doi:10.1371/journal.pone.0013764
Editor: Oliver Eickelberg, Helmholtz Zentrum Mu ¨nchen/Ludwig-Maximilians-University Munich, Germany
Received June 1, 2010; Accepted October 4, 2010; Published October 29, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by National Institutes of Health intramural funds. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: David_Schrump@nih.gov
Introduction
Genetic as well as epigenetic dysregulation of gene expression
during malignant transformation is attributable in part to aberrant
expression of micro-RNAs (miRNAs) [1,2]. These small (,21-mer)
non-coding RNA molecules regulate gene expression by binding to
39 untranslated regions (39 UTR) of target mRNAs, triggering
transcript degradation or translational repression depending on
the extent of complementarity between the seed sequence of
the miRNA and the mRNA motif [3]. Approximately 30% of all
mRNAs are potential miRNA targets. To date, more than 800
miRNAs have been identified in humans, each of which targets
multiple functionally-related genes, thus mediating complex
regulatory networks [3,4].
A variety of miRNAs have been implicated in the pathogenesis
of human lung cancers, the vast majority of which are directly
attributable to cigarette smoking [5,6]. Some of these miRNAs
function as oncogenes (oncomirs), whereas others act as tumor
suppressors. For example, miR-21, which is activated in part
via aberrant EGFR signaling represses expression of PTEN and
PDCD4, facilitating proliferation, invasion, and resistance to
apoptosis of lung cancer cells [7–11]. Activation of miR-93, miR-
98 and miR-197 inhibits expression of FUS1, enhancing cell cycle
progression and chemo-resistance in lung cancer cells [12,13].
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and E, abrogates Rb-mediated cell cycle regulation in lung cancer
cells [14]. Furthermore, down-regulation of let-7 family members
targeting numerous mRNAs encoding cell cycle regulatory proteins
such as Ras, AURKA, AURKB, and E2F5 enhances proliferation
and tumorigenicity of lung cancer cells [7,15,16]. Interestingly,
several miRNA alterations frequently observed in lung cancers, such
as down-regulation of let-7 and over-expression of miR-17-92, are
detected in cancer stem cells [17,18] as well as pseudoglandular lung
parenchyma [19], suggesting embryonic reprogramming of miRNA
expression during pulmonary carcinogenesis.
Despite recent studies demonstrating miRNA expression pro-
files correlating with tumor histology, as well as smoking status and
prognosis of patients with primary lung cancers, [6,20–22], limited
information is available regarding miRNA alterations that directly
contribute to initiation and early progression of these malignan-
cies. In the present study, we utilized an in-vitro model system to
examine miRNA alterations mediated by cigarette smoke con-
densate (CSC) in normal human respiratory epithelia, and lung
cancer cells derived from smokers as well as nonsmokers. Herein,
we report that CSC induces expression of miR-31 targeting several
Wnt signaling antagonists including Dickkhopf-1 (Dkk-1) and
DACT3 in normal human respiratory epithelia as well as lung
cancer cells. These observations provide a direct mechanistic link
between cigarette smoke and activation of an oncomir suppressing
antagonists of stem cell signaling during tobacco-induced pulmo-
nary carcinogenesis.
Materials and Methods
Cell lines and treatment conditions
All lung cancer lines were obtained from American Type Culture
Collection (ATCC; Manassas, VA), and maintained in RPMI
medium supplemented with 10% FCS, 10 mM of glutamic acid,
and 1% penicillin/streptomycin. Primary normal human small
airway epithelial cells (SAEC) and normal human bronchial
epithelial cells (NHBE) were obtained from Lonza, Inc (Frederick,
MD), and cultured per vendor instructions. Immortalized human
bronchial epithelial cells (HBEC) were generously provided by
John D. Minna (U-T Southwestern, Dallas, TX), and cultured in
complete Keratinocyte-SFM media (Invitrogen, Carlsbad, CA)
supplemented with 5 mg/L epidermal growth factor (EGF) and
50 mg/L bovine pituitary extract (BPE). Cigarette smoke conden-
sates (CSC) derived from Kentucky Reference 3R4F research blend
cigarettes (University of Kentucky) were prepared as described [23],
and resuspended at a concentration of 1 mg tar/mL in RPMI,
which was defined as 10% CSC [24]. For smoke exposure
experiments, cells were cultured in 10-cm dishes in appropriate
normal media (NM) with or without CSC (1%). Medium was
changed daily with the addition of fresh CSC. Cells were
subcultured as necessary, and harvested at various time-points for
analysis.
Human tissues
Primary lung cancer specimens and adjacent histologically
normal lung parenchyma were harvested intra-operatively from
patients undergoing potentially curative resections on NIH internal
review board–approved protocols, requiring written informed con-
sent. All tissues were immediately snap-frozen with a portion of
harvested tissue sent for immediate histologic confirmation by an
independent, anatomic pathologist in a blinded manner. Tissue
specimens were bar-coded and stored in the Thoracic Oncology
Laboratory, Surgery Branch, NCI. For microRNA isolation and
expression analysis, the small RNA fraction was isolated with the
RT2 qPCR-Grade miRNA Isolation kit (Qiagen; Valencia, CA),
and miRNA expression was quantified with the qRT-PCR miRNA
Detection Kit (ABI; Carlsbad, CA).
miRNA overexpression and inhibition
Precursor and inhibitor miRNAs pMiR-H31PA-1, pCDH-CMV-
MCS-EF1-copGFP negative control, MZIP31-PA-1, pGreenPuro
Scramble Hairpin negative control were purchased from SBI (System
Biosciences, Mountain View, CA). miRNA precursors or inhibitors
(both at 50 nM) were transfected into cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA).
Reporter vectors and DNA constructs
The 39 UTRsof Dkk1 (850 bp) and DACT3(2461 bp) werePCR
amplified from human SAEC cDNA, and inserted downstream of
CMV-driven firefly luciferase cassette in the pMIR-REPORT
vector (Ambion, Austin, TX) between Hind III and Spe I sites.
Mutant reporter plasmids (39 UTRs of Dkk1 and DACT3) were
created by using QuikChange Site-Directed Mutagenesis Kit
(Stratagene, Wilmington, DE). All insert fragments were confirmed
by direct sequencing.
Luciferase miRNA target reporter assays
For miRNA target validation, approximately 2610
4 SAEC cells
per well in 24-well plates were transiently transfected with 25
to 50 ng of each firefly luciferase reporter construct (Promega,
Madison, WI), 150 to 175 ng pcDNA3 empty vector, 200-ng
pRTK-Luc (Promega) as internal control, and 30 pmol of pre-
miR-31 (SBI, Mountain View, CA). Renilla luciferase vector was
used to normalize transfection efficiency. Approximately 24 hours
after transfection, firefly and Renilla luciferase activities were
assayed. Normalized relative light units represent firefly luciferase
activity/Renilla luciferase activity.
Proliferation assays
Cells were plated at a concentration of 5610
4 cells per well in
24-well plates and cultured in NM with or without CSC plus
plasmid transfection. Triplicate wells were harvested and counted
by trypan blue exclusion techniques.
Quantitative RT-PCR
For mRNA, total RNA was prepared using TRIzol reagent
(Invitrogen) and genomic DNA was eliminated with TURBO
DNA-free Kit (Ambion). One mg of total RNA was reverse
transcribed using iScript reverse transcriptase (Bio-Rad). Omission
of reverse transcriptase served as a negative control. cDNA was
amplified using Platinum PCR SuperMix (Invitrogen). PCR was
performed as follows: 5 min at 94uC, 35 cycles of 60 s at 94uC,
60 s at 57–60uC, and 60 s at 72uC, followed 5 min at 72uC. Real-
time quantitative RT-PCR analysis was done as described [25]
using Dkk-1, DACT3, SFRP1, SFRP4, WIF-1, and b-actin
primers from Applied Biosystems or Integrated DNA Technolo-
gies (Coralville, IA). For microRNA isolation and expression
analysis, expression of miRNA isolated with the RT2 qPCR-
Grade miRNA Isolation kit (Qiagen) was quantified with the qRT-
PCR miRNA Detection Kit (ABI).
Chromatin immunoprecipitation (ChIP)
Cells were crosslinked with 1% formaldehyde, lysed and
sonicated on ice to generate DNA fragments with an average
length of 200–800 bp [26]. After pre-clearing, 1% of each sample
was saved as input fraction. Immunoprecipitation was performed
using antibodies specifically recognizing H3K4me3, H3K9Ac,
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DNA was eluted and purified from complexes, followed by PCR
amplification of the LOC554202 promoter using primers and
conditions as described [27].
siRNA and shRNA knockdown
Calu-6 and H841 cells were transiently transfected with siRNAs
targeting C/EBP-a and C/EPB-b, or sham siRNA sequences
(Dharmacon, Lafayette, CO) using Lipofectamine 2000 (Invitro-
gen). Target gene knockdown was confirmed by RT-PCR and
western blot techniques.
Western blot analysis
Protein extracts were generated as previously described [26].
Samples were separated on 4–12% Tris-glycine SDS-polyacryl-
amide gel electrophoresis gels and blotted onto Immobilon P
membrane (Millipore, Billerica, MA); proteins were detected using
enhanced chemiluminescence detection reagents (Amersham Bio-
sciences, Piscataway, NJ). Antibodies used for western analysis
were goat anti-Dkk-1, mouse anti-DACT3, and goat anti-b-actin
(Santa Cruz Biotechnology Inc., Santa Cruz, CA).
RT-PCR arrays
Wnt signaling RT-PCR super-arrays (PAH-043A) were ob-
tained from SABiosciences (Frederick, MD). 1 mg of total RNA
was used for reverse transcription and the entire cDNA reaction
was diluted and distributed amongst the 96 wells of the super-array
plate. The reactions were performed with RT
2 SYBR Green/
ROX PCR Master Mix (SABiosciences). Results were analyzed
using software provided by the vendor http://www.sabiosciences.
com/pcr/arrayanalysis.php.
MicroRNA microarray analysis
Low molecular RNAs (small RNAs) were extracted from cell
plates using mirVana
TM miRNA isolation kit (Ambion, Austin,
TX) using the miRNA enrichment method according to the
manufacturer’s protocol. Three hundred nanograms of small
RNAs from tissue samples were directly labeled with N-code
miRNA labeling kit (Invitrogen) per vendor’s protocols. Briefly,
mature miRNAs in the small RNA samples were first tailed with
poly (A); poly (A) tailed miRNAs were then tagged with a capture
sequence followed by hybridization to Cy5/Cy3 labeled 3DNA
dendrimers. For microarray data processing and normalization,
microarray chips were scanned using a GenePix 4000B scanner
(Axon Instruments, Union City, CA) and median spot intensities
were generated using GenePix 5.0 (Axon Instruments, Union City,
CA). Microarray data were processed and normalized (50%) using
GeneSpring (Agilent, CA). Statistic and clustering analyses were
performed using GeneSpring software. Expression levels of
miRNAs were subjected to 2-way analysis of variance (Anova)
for CSC treated vs untreated conditions for the various cell lines.
Ago CLIP (Identification of AGO-1-associated mRNAs)
Cells were harvested and CLIP experiments were performed us-
ing either anti-AGO family or elF2C antibodies as described (28).
Briefly, cells were cross-linked with irradiation for 400 mJ/cm
2
and additional 200 mJ/cm
2 in Stratalinker, and lysed to generate
RNA/protein (AGO) complexes [28–30]. After pre-clearing, 1%
of each sample was saved as input fraction. Immunoprecipitation
was performed using specific antibodies against either AGO family
(Millipore, Billerica, MA), or elF2C (Santa Cruz Biotechnology,
Inc.), or control IgG. RNA was isolated and purified from
complexes, followed by PCR amplification of 39 UTRs of miR-31
targets.
Murine xenograft experiments
Calu-6 and H358 cells transfected with pCDH-CMV-MCS-
EF1-copGFP vector control and pMiR-H31PA-1 were suspended
in PBS at a concentration of 1610
6 cells/100 mL, and inoculated
subcutaneously into contralateral flanks of athymic nude mice (10
mice per treatment group per experiment). Mice were monitored
twice weekly and tumor volumes were calculated on the basis of
perpendicular diameters. Approximately 21 days and 35 days later
for Calu-6 and H358 experiments, respectively, mice were
euthanized, and evaluated for percent tumor take, and mass of
excised xenografts. Thereafter, tumor tissues were snap frozen in
liquid nitrogen, and stored for future analysis. All animal
procedures were approved by the National Cancer Institute
Animal Care and Use Committee, and were in accordance with
the NIH Guide for the Care and Use of Laboratory Animals.
Statistical Analysis
Differences between matched samples from the same lung
cancer patients, such as tumor and normal tissue were tested with
the signed-rank test. Groups were compared with the Wilcoxon–
Mann-Whitney test. Confidence intervals for the differences in
medians between two groups were computed by the bias-corrected
and accelerated bootstrapping methods. Differences in tumor
volumes between opposing flanks of tumor-bearing mice were
tested with the Wilcoxon-signed rank test at 5-day intervals.
P values were adjusted for multiple testing by complete resampling
[31]. Confidence intervals for the median of flank differences were
computed as exact non-parametric two-tailed confidence intervals
based on the Wilcoxon signed-rank test.
Primer Sequences
Submitted as Table S1.
Results
Up-regulation of miR-31 in cultured cells exposed to CSC
Preliminary experiments using array techniques were performed
to examine miRNA expression profiles in a panel of normal
respiratory epithelia (SAEC and NHBE), immortalized human
bronchial epithelial cells (HBEC) and lung cancer cells (Calu-6,
H841, H1299, H1650, and H1975) cultured in normal media with
or without CSC. This analysis revealed unique basal miRNA
expression profiles coinciding with histology (normal vs malignant).
Furthermore, lung cancer lines derived from smokers (Calu-6,
H1299, H841) were readily distinguished from those from non-
smokers (H1650, H1975) (M. Yang, manuscript in preparation).
Of particular interest, aforementioned micro-array experiments
suggested that CSC treatment induced expression of miR-31 in
normal respiratory epithelia as well as lung cancer cells. To further
investigate this phenomenon, quantitative RT-PCR (qRT-PCR)
experiments were performed to examine miR-31 expression in
SAEC, HBEC, Calu-6, and H841 cells cultured in normal me-
dia (NM) with or without CSC for 5 days. These experiments
(Figure 1A) demonstrated that untreated Calu-6 and H841cells
exhibited higher endogenous levels of miR-31 relative to SAEC
and HBEC cells; additional analysis revealed that 5 day CSC
exposure up-regulated miR-31 expression 5.5 fold and 3.6 fold in
SAEC and HBEC, respectively relative to controls. Similar
treatment increased miR-31 expression 3.1 and 6.5 fold in Calu-
6 and H841 cells, respectively (Figure 1B). Time course experi-
ments revealed up-regulation of miR-31 in SAEC and H841 cells
within 24 h following initiation of CSC exposure, with expression
peaking and leveling off approximately 96 h later (Figure 1C).
miR-31 and Lung Cancer
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days following removal of CSC from culture media (Figure 1B).
miR-31 expression in primary lung cancer specimens
Additional qRT-PCR experiments were performed to examine
miR-31 expression levels in a randomly selected panel of primary
non-small cell lung cancers and adjacent histologically normal
lung parenchyma (clinical and pathologic data summarized
in Table 1). As shown in Figure 1D, miR-31 expression was
increased (mean 4.13 fold; range 1.47–12.46 fold) in lung cancers
relative to paired normal lung tissues. Interestingly, miR-31 levels
in lung cancers from smokers were higher than those observed in
non-smokers (5.2 vs 1.65 fold, respectively; p,0.01). Collectively,
these data confirmed preliminary experiments demonstrating
higher levels of miR-31 expression in lung cancer cells relative
to cultured normal respiratory epithelia (Figure 1A), and suggested
that activation of miR-31 might be a biologically-relevant
phenomenon during human pulmonary carcinogenesis.
Effects of miR-31 on antagonists of WNT signaling
Software-guided analysis demonstrated that several antagonists
of Wnt signaling including Dkk-1[32] and DACT3[33] were
potential miR-31 targets. To confirm these results, SAEC, HBEC,
Calu-6, and H841 cells were transiently transfected with miR-31.
Quantitative RT-PCR experiments revealed ,12 fold increases in
miR-31 expression in miR-31-transfected cells relative to vector
controls (Figure 2A). Over-expression of miR-31 decreased Dkk-1
as well as DACT3 (,5–8 fold and ,1.5–7 fold, respectively,
relative to controls) in these four cell lines (Figures 2B). These
effects appeared somewhat more pronounced in normal SAEC
and immortalized HBEC, possibly due to lower levels of
Figure 1. Expression of miR-31 in cultured cells exposed to
CSC, primary lung cancers and adjacent normal lung tissues. A)
qRT-PCR analysis of endogenous miR-31 expression normalized with
control miRNA (RNU44) in SAEC, HBEC, Calu-6, and H841cells. Basal
levels of miR-31 are higher in lung cancers relative to cultured normal or
immortalized human respiratory epithelial cells. B) qRT-PCR analysis of
miR-31 expression in SAEC, HBEC, Calu-6, and H841cells cultured in
normal media (NM) with or without CSC for 5 days. Increased miR-31
Table 1. Clinicopathologic characteristics of 10 lung cancer
patients used for miR31 analysis
*.
Characteristic N (%)
Sex Male 1 (10)
Female 9 (90)
Age, y** 66.2 (46–85)
Tumor types Adenocarcinoma 9 (90)
Squamous cell carcinoma 1 (10)
Stage T1–T2 8 (80)
T3–T4 2 (20)
N0–N1 9 (90)
N2 1 (10)
Smoking history Yes 7 (70)
No 3 (30)
*All lung cancer patients underwent surgery with curative intent.
**Age is reported as mean (range).
doi:10.1371/journal.pone.0013764.t001
expression was evident 20 days following discontinuation of CSC
treatment. C) qRT-PCR analysis demonstrating time-dependent activa-
tion of miR-31 in SAEC and H841cells cultured in NM with or without
CSC for 0, 12, 24, 48, 72, 96, and 120 hours. D) qRT-PCR analysis
demonstrating miR-31 expression in human lung cancers relative to
paired adjacent normal lung tissues. miR-31 levels in tumors were
higher than corresponding normal lung. Furthermore, miR-31 levels
were significantly higher in lung cancers from active/former smokers
compared to those from never-smokers.
doi:10.1371/journal.pone.0013764.g001
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PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13764Figure 2. miR-31 negatively regulates WNT signaling pathway antagonists in normal respiratory epithelia and lung cancer cells. A)
miR-31 was over-expressed in SAEC, HBEC, Calu-6, and H841 cells via transient transfection of primary miR-31 constructs. qRT-PCR analysis confirmed
high level miR-31 expression in miR-31-transfected relative to control cells. B) qRT-PCR analysis of Dkk-1 and DACT3 expression levels in SAEC, HBEC,
Calu-6, and H841 cells with or without over-expression of miR-31. Over-expression of miR-31 decreased Dkk-1 and DACT3 in all four cell lines. C) qRT-
PCR analysis demonstrating decreased levels of endogenous miR-31 in SAEC, HBEC, Calu-6, and H841 cells following transient transfection of
antisense-miR-31(Zip-miR-31) constructs relative to controls. D) qRT-PCR analysis of Dkk-1 and DACT3 expression levels in SAEC, HBEC, Calu-6 and
H841 cells with or without down-regulation of miR-31. Knock-down of miR-31 enhances basal levels of Dkk-1 and DACT3 in these cells. E) qRT-PCR
analysis demonstrating that knockdown of miR-31 partially blocks CSC-mediated decreases of Dkk-1 and DACT3 in SAEC. F) Western blot analysis of
Dkk-1 and DACT3 expression in parental and vector control SAEC and Calu-6 cells, as well as SAEC and Calu-6 cells exhibiting constitutive over-
expression or knock-down of miR-31. Densitometry values are normalized to b-actin control. Dkk-1 and DACT3 level were decreased, or somewhat
enhanced in these cells following over-expression, or knock-down of miR-31, respectively.
doi:10.1371/journal.pone.0013764.g002
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these cells relative to Calu-6 and H841 lung cancer cells.
Subsequent experiments were undertaken to determine if deple-
tion of endogenous miR-31 affected expression of Dkk-1 and
DACT3 in cultured respiratory epithelial cells. As shown in
Figure 2C, miR-31 expression levels were reduced ,7–10 fold in
SAEC, HBEC, Calu-6, and H841 cells transiently transfected with
antisense-miR-31 (Zip-miR-31) constructs relative to vector
controls. Reduction of miR-31 expression increased Dkk-1 as well
as DACT3 expression in these cell lines (,1.47–8 fold and ,4.7–9
fold respectively; Figure 2D). Subsequent experiments revealed
that knockdown of miR-31 significantly attenuated CSC-mediated
decreases in Dkk-1 and DACT3 in SAEC as well as H841 cells
(Figure 2E). Consistent with aforementioned results, western blot
analysis revealed that Dkk-1 and DACT3 protein levels in SAEC
and Calu-6 cells were decreased by over-expression of miR-31
(Figure 2F). In contrast, knock-down of endogenous miR-31
appeared to increase Dkk-1 and DACT3 protein levels in SAEC
and Calu-6 cells, although these changes did not correlate pre-
cisely with alterations in mRNA expression, possibly due, in
part, to protein stability and antibody affinities. Collectively, these
experiments strongly suggested that miR-31 modulates Dkk-1
and DACT3 via post-transcriptional and translational-inhibitory
mechanisms in cultured normal respiratory epithelia and lung
cancer cells.
Super-arrays were used to further examine the effects of miR-31
on Wnt signaling in SAEC and Calu-6 cells. This analysis revealed
7–14 fold down-regulation of Dkk-1, as well as additional anta-
gonists of Wnt signaling including SFRP1, SFRP4, and WIF1, as
well as a 5 fold increase in CTNNB1, TCF7 and Wnt-5a (data
available on request). Subsequent qRT-PCR experiments con-
firmed repression of SFRP1, SFRP4, and WIF-1, and up-
regulation of Wnt-5a in SAEC and Calu-6 cells over-expressing
miR-31 (Figure S1A). Collectively, these data suggest that miR-31
activates Wnt signaling in cultured lung cancer and normal
respiratory epithelial cells.
Dkk-1 and DACT3 are direct target candidates of miR-31
Additional experiments were undertaken to examine if miR-31
directly interacts with 39 UTRs of Dkk-1 and DACT3. Briefly,
RNA cross-link immunoprecipitation (CLIP) techniques were used
to detect interaction of miR-31 with these potential targets in
SAEC cells [28]. Figure 3A depicts the potential miR-31 binding
sites within the 39 UTRs of Dkk-1 and DACT3 transcripts. RT-
PCR analysis revealed that the AGO family antibody precipitated
Dkk-1 and DACT3 transcripts in the cytoplasm of untreated
SAEC (Figure 3B). Obvious increases in PCR products corre-
sponding to 39 UTRs of Dkk-1 and DACT3 were observed
in SAEC over-expressing miR-31; this phenomenon was not
observed in miR-31-depleted SAEC cells. In these experiments, b-
actin served as the negative control since no sequences can be
targeted by miR-31 (Figure 3B). Because miR-21 has been found
to directly target the 39 UTR of PDCD4 human tissues [34],
immunoprecipitated RNA from SAEC cells over-expressing miR-
21 served as a positive control for CLIP (data not shown).
Consistent with aforementioned Wnt SuperArray results, addi-
tional CLIP experiments demonstrated interaction of miR-31 with
SFRP4 (Figure S1B).
Additional experiments were performed using pMiR-Report
vectors with wt or mutant 39 UTRs of Dkk-1 or DACT3,
transiently co-transfected with miR-31 primary constructs or
control vectors into SAEC. As shown in Figure 3C, luciferase
activities of wt 39 UTRs of Dkk-1 and DACT3 were reduced
,70% compared with vector control or mutated 39 UTRs,
respectively. Collectively, these experiments strongly suggest that
miR-31 directly interacts with 39 UTRs of Dkk-1 and DACT3.
Epigenetic alterations coinciding with CSC-mediated
activation of miR-31
Recent ChIP analysis of distribution patterns of H3K4Me3,
H3K9/14Ac, and H2AZ suggested that the host gene for miR-31 is
LOC554202 [35]. As such, additional experiments were performed
to examine if CSC modulated expression of LOC554202 in SAEC.
Consistent with results pertaining to miR-31 (Figure 1A), 5-day
CSC treatment induced expression of LOC554202, which was
maintained for 20 days following removal of CSC from culture
media (Figure 4A); these results were consistent with those
pertaining to CSC-mediated up-regulation of miR-31 (Figure 1).
qRT-PCR experiments revealed that 6 of 7 primary lung cancer
specimens expressing $2 fold higher miR-31 levels relative to
paired normal lung tissues also exhibited over-expression of
LOC554202 (Figure 4B).
Sequence analysis revealed no classic CpG island in the
promoter region of LOC554202, suggesting that this host gene
is not regulated primarily via DNA methylation mechanisms (data
not shown). Subsequent ChIP experiments demonstrated in-
creased levels of H3K4Me3 and H3K9/14Ac activation marks in
the proximal promoter region (0 to 21.5 k) of LOC554202 (which
presumably contains the regulatory elements for miR-31) in SAEC
following CSC exposure (Figures 4C and D). Interestingly, these
activation marks in the LOC554202 promoter region in SAEC
were still present 20 days following cessation of CSC treatment.
These findings were consistent with RT-PCR results depicted in
Figure 4A.
Role of C/EBP-b in CSC-mediated activation of miR-31
Additional experiments were performed to further examine
mechanisms by which CSC mediates activation of LOC554202.
Preliminary software analysis revealed no characteristic XRE
sequences within 5 kb of the presumed transcription start site
(TSS) for LOC554202, suggesting that up-regulation of LOC554202
by CSC was not mediated primarily via aryl hydrocarbon receptor
signaling [36]. However, as shown in Figure 5A, this analysis revealed
multiple potential binding sites for C/EBP-b, which has been shown
previously to mediate up-regulation of Bcl-xL in breast cancer cells
exposed to cigarette smoke [37]. As such, additional experiments
were performed to ascertain if this transcription factor contributed to
CSC-mediated activation of miR-31 in cultured respiratory epithelia.
qRT-PCR experiments revealed that CSC enhanced C/EBP-b - but
not CEBP/a expression in SAEC as well as Calu-6 cells (Figure 5B).
In additional experiments, siRNA techniques were used to inhibit C/
EBP expression in these cells. Preliminary experiments confirmed
specificity of siRNAs targeting C/EBP-b and C/EBP-a (Figure 5C).
Control experiments demonstrated up-regulation of Bcl-xL expres-
sion in SAEC and Calu-6 cells by CSC exposure, and complete
abrogation of CSC-mediated induction of Bcl-xL expression in these
cells following knock-down of C/EBP-b (Figure 5D; left panel).
Knockdown of C/EBP-b also markedly attenuated CSC-mediated
activation of LOC554202 in these cells; this phenomenon was
considerably less pronounced following knock-down of CEBP-a
(Figure 5D; right panel).
Quantitative ChIP experiments were next performed to
examine if CSC induces recruitment of C/EBP-b to the
LOC554202 promoter. Preliminary control experiments revealed
increased occupancy of C/EBP-b within the Bcl-xL promoter in
SAEC and Calu-6 cells following CSC exposure (Figure 5E; left
panel). Subsequent experiments demonstrated enrichment of
C/EBP-b within the promoter region of LOC554202 in SAEC
miR-31 and Lung Cancer
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panel). Collectively, these data strongly suggest that C/EBP-b
contributes to up-regulation of LOC554202 and miR-31 by CSC.
Effects of miR-31 on proliferation and tumorigenicity of
human lung cancer cells
Additional experiments were undertaken to ascertain if miR-31
enhances the malignant phenotype of lung cancer cells. First, in-
vitro growth assays were performed using Calu-6 and H841 cells
exhibiting over-expression or depletion of miR-31. As shown in
Figures 6A and B, constitutive over-expression of miR-31
increased proliferation of Calu-6 (35%) and H841(55%) relative
to vector controls; in contrast, knock-down of endogenous miR-31
mediated ,30% growth inhibition of these cancer cells. Addi-
tionally, Calu-6 as well as H358 cells stably-transfected withmiR-31
or vector controls were inoculated subcutaneously in contralateral
flanks of athymic nude mice (10 per group). As shown in Figures 6C
and D, constitutive over-expression of miR-31 markedly increased
volumes and masses of H358 as well as Calu-6 xenografts relative to
control vectors (p,0.01). Collectively, these experiments strongly
suggest that miR-31 enhances the malignant phenotype of human
lung cancer cells.
Discussion
The vast majority of lung cancers are directly attributable to
cigarette abuse [38]; furthermore, a substantial number of lung
Figure 3. WNT signaling pathway antagonists are direct target candidates of miR-31. A) Putative target sites of miR-31 within Dkk-1 39
UTR (top) and DACT3 39 UTR (bottom). B) miRNA-targeted transcripts in RISC were precipitated with AGO family antibodies after UV induced cross-
linking of RNAs to their binding proteins, followed by RT-PCR amplification. Over-expression of miR-31 significantly increased precipitation of Dkk-1
and DACT3 target transcripts in SAEC cells. b-actin served as the negative control since no sequences in the 39 UTR that can be targeted by miR-31. C)
Luciferase assays demonstrating reduction in luciferase activity in SAEC transfected with pMiR-Report vectors with or without insertion 39 UTR or
mutated 39 UTR of WNT signaling antagonists.
doi:10.1371/journal.pone.0013764.g003
miR-31 and Lung Cancer
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13764cancers in never-smokers are due to environmental tobacco
exposure (passive smoking) [39]. An estimated 1.3 billion people
smoke worldwide, and the prevalence of smoking, as well as
environmental tobacco exposures are increasing at an alarming
rate [40]. The overall five-year survival rate for lung cancer
patients is approximately 15 percent [41]. These data warrant
continued efforts to define genetic as well as epigenetic
mechanisms contributing to pulmonary carcinogenesis, and to
identify novel molecular targets for the treatment and prevention
of lung cancer.
In the present study, an in-vitro model system was used to gain
insight regarding miRNA alterations potentially contributing to
initiation and early progression of tobacco-induced lung cancers.
Our analysis revealed consistent activation of miR-31 in normal
respiratory epithelia and lung cancer cells derived from smokers as
well as never-smokers. Subsequent analysis revealed over-expression
of miR-31 in primary human lung cancer specimens –particularly
those from smokers, relative to adjacent normal parenchyma.
Interestingly, up-regulation of miR-31 has been observed in
pulmonary adenomas or normal lung tissues from mice exposed to
vinyl carbamate, or environmental smoke, respectively [42,43].
Until recently, limited information has been available regarding
mechanisms modulating miRNA expression during malignant
transformation, primarily due to difficulties pertaining to identi-
fication of promoters and transcription start sites (TSS). RNA
polymerase II (RNAPII) appears to regulate several miRNAs
including miR-21 and miR-17, whereas RNA polymerase III
(RNAPIII) has been implicated in the regulation of C19MC and
other miRNAs within or adjacent to DNA repeats [44]. Upstream
sequencing of miRNAs by RNAPII ChIP-chip techniques re-
vealed that LOC554202, which maps to 9p21.3, shares a TSS
with miR-31, and acts as its host gene [35]. Consistent with these
observations, qRT-PCR and ChIP experiments presented in this
manuscript demonstrated that CSC-mediated up-regulation of
miR-31 coincides with activation of LOC554202.
Whereas several reports have documented up-regulation of
miR-31 in cultured lines or tissues derived from oropharyngeal,
esophageal, lung, or colorectal carcinomas [45–48], our experi-
ments appear to be the first to directly examine mechanisms
regulating expression of this miRNA and its host gene in human
lung cancer. Notably our analysis revealed a critical role for C/
EBP-b in activation of miR-31 and LOC554202 by cigarette
smoke. C/EBP-b, which exists as several isoforms exhibits highly
pleiotropic roles in normal tissue homeostasis and cancer. Recent
studies indicate that C/EBP-b is a master regulator of mesenchy-
mal transformation and aggressive phenotype of human glioma
Figure 4. Epigenetic alterations coinciding with CSC-mediated activation of miR-31. A) RT-PCR analysis demonstrating up-regulation of
LOC554202 expression in SAEC following 5-day CSC exposure. Consistent with data pertaining to up-regulation of miR-31 by CSC, expression of
LOC554202 persisted for 20 days following cessation of CSC exposure. B) qRT-PCR analysis demonstrating expression levels of LOC554202 in primary
lung cancers relative to adjacent normal lung tissues. C) Schematic representation of LOC554202, the putative host gene of miR-31. A, B, C, and D
represent positions of paired primers used for ChIP analysis. D) ChIP analysis depicting H3K4Me3 and H3K9/14 acetylation levels within four regions
of the LOC554202 promoter (,1 kb, 2 kb, 3 kb, and, 5 kb from the TSS) in SAEC cultured with or without CSC. Increased activation marks were
observed in the proximal promoter region following CSC exposure.
doi:10.1371/journal.pone.0013764.g004
miR-31 and Lung Cancer
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13764Figure 5. C/EBP-b mediates CSC-induced miR-31 transcription. A) Schematic representation of putative binding sites of C/EBP-b (vertical bars)
in the LOC554202 promoter. The arrows show the positions of ChIP primers for C/EBP-b. B) qRT-PCR analysis demonstrating that CSC enhances C/
EBP-b but not C/EBP-a expression in SAEC and Calu-6 cells. C) qRT-PCR analysis demonstrating specificity of siRNAs targeting C/EBP-b and C/EBP-a in
SAEC and Calu-6 cells. D) Left panel: qRT-PCR analysis of Bcl-xL expression in SAEC and Calu-6 cells cultured in the presence or absence of CSC
following knock-down of C/EBP-b or C/EBP-a. CSC exposure dramatically increases Bcl-xL expression in SAEC and Calu-6 cells. Knock-down of C/EBP-b
expression decreases activation of Bcl-xL by CSC. This phenomenon was not nearly as dramatic following knock-down of C/EBP-a. Right panel: qRT-
PCR analysis of LOC554202 expression in SAEC and Calu-6 cells cultured in the presence or absence of CSC following knock-down of C/EBP-b or
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and pro-metastatic genes, enhancing resistance to apoptosis in
multiple myeloma and prostate carcinoma cells [50,51]. Further-
more, C/EBP-b regulates energy balance, and promotes growth of
colon cancer cells in part via activation of IGF-1, insulin, and
leptin [52]. Lastly, C/EBP-b activates Bcl-xL expression in breast
and lung cancer cells exposed to CSC [37] (and our current
experiments). The specific isoforms of C/EBP-b activating miR-31
and LOC554202, and the mechanisms mediating prolonged up-
regulation of this miRNA and its host gene in respiratory epithelia
and lung cancer cells following CSC exposure are a focus of
ongoing investigation in our laboratory.
Shortly before this manuscript was initially submitted for pub-
lication, Liu et al [47] reported a series of experiments dem-
onstrating up-regulation of miR-31 in lung cancer cells derived
from cyclin E-transgenic mice. Subsequent experiments revealed
over-expressionofmiR-31inhumanlungadenocarcinomas.Knock-
down of miR-31 inhibited proliferation of mouse and human lung
cancer cells, and diminished clonogenicity and tumorigenicity of
murine lung cancer cells. The oncogenic effects of miR-31 in lung
cancer cells were attributed to inhibition of large tumor suppressor 2
(LATS2) and PP2A regulatory subunit B alpha (PPP2R2A).
Our current data are consistent with, and extend these findings
by demonstrating an additional potential mechanism by which
miR-31 contributes to pulmonary carcinogenesis, namely activa-
tion of Wnt signaling. Our previous studies have demonstrated
that CSC induces polycomb-mediated repression of Dkk-1 in lung
cancer cells and cultured normal respiratory epithelia [32]. CSC-
exposure as well as Dkk-1 knock-down enhances Wnt-5a
expression, and significantly increases proliferation and tumorige-
nicity of lung cancer cells. Our current data indicate that miR-31
directly inhibits expression of Dkk-1 and DACT3 in lung cancer
cells as well as normal respiratory epithelia; furthermore, miR-31
over-expression in these cells depletes several other antagonists of
Wnt signaling with potential miR-31 binding motifs including
SFRP1, SFRP4, and WIF-1, which are frequently silenced in
human lung cancers [53]. In addition, up-regulation of miR-31
mediates expression of the non-canonical ligand Wnt5a, which
induces epithelial-to-mesenchymal transition (EMT), and dramat-
ically enhances the malignant phenotype of lung cancer cells
Figure 6. miR-31 functions as an oncomir in lung cancer cells. A/B) Direct cell count assays depicting in-vitro proliferation of Calu-6 and H841
lung cancer cells exhibiting over-expression or knock-down of miR-31. Constitutive over-expression of miR-31 increased proliferation, whereas knock-
down of miR-31 diminished proliferation of Calu-6 (a) as well as H841 (b) cells relative to vector controls. C) Growth of H358 and Calu-6 tumor
xenografts in nude mice. Calu-6 and H358 cells constitutively over-expressing miR-31 and vector controls (1610
6) were inoculated subcutaneously in
the right and left flanks of athymic nude mice. Tumor volumes were determined every five days. The mean tumor volumes are shown. Volumes of
xenografts derived from Calu-6 or H358 cells over-expressing miR-31 were significantly larger than vector controls (P,0.01). D) Tumor masses from
H358 and Calu-6 xenografts. MiR-31 expression significantly increased average mass of H358 as well as Calu-6 xenografts (p,0.001).
doi:10.1371/journal.pone.0013764.g006
C/EBP-a. CSC exposure dramatically increases LOC554202 expression in SAEC and Calu-6 cells. Knock-down of C/EBP-b expression virtually abolishes
activation of LOC554202 by CSC in SAEC as well as Calu-6 cells. This phenomenon was considerably less apparent following knock-down of C/EBP-a.
E) Left panel: ChIP analysis demonstrating enrichment of C/EBP-b within the Bcl-xL promoter in SAEC and Calu-6 cells following CSC exposure. Right
panel: ChIP analysis demonstrating enrichment of C/EBP-b in the LOC554202 promoter in SAEC and Calu-6 cells following CSC exposure.
doi:10.1371/journal.pone.0013764.g005
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vations suggest that miR-31 cooperates with epigenetic mecha-
nisms to silence Wnt antagonists, thereby activating signaling
networks implicated in maintenance of normal as well as cancer
stem cells [54,55] during initiation and progression of tobacco-
induced lung cancers. These issues are a focus of ongoing ex-
periments in our laboratory.
Our findings, as well as those of Liu et al [47] are consistent with
data demonstrating that up-regulation of miR-31 in oropharyn-
geal and colorectal carcinomas correlates with advanced stage of
disease, and decreased survival of patients with these malignancies
[45,48]. On the other hand, our data differ from those reported by
Valastyan et al [56], Creighton et al [57], and Ivanov and
colleagues [58], who have observed that miR-31 functions as a
tumor suppressor in breast and ovarian carcinomas, as well as
malignant pleural mesotheliomas. Discrepancies regarding our
findings and those of the latter investigators may be attributable in
part to genetic and epigenetic profiles of the various malignancies,
reprogramming [59], tissue-specific effects of basal and inducible
miR-31 expression, and Wnt signaling [60,61]. Further studies
are necessary to fully define the role of miR-31 in human
malignancies, and specifically determine the prognostic and
predictive significance of miR-31 expression during pulmonary
carcinogenesis.
Supporting Information
Figure S1 A) qRT-PCR analysis demonstrating that over-
expression of miR-31 decreases SFRP1, SFRP4 and WIF-1, and
enhances Wnt5a expression in SAEC and Calu-6 cells. B) CLIP
analysis revealing interaction of miR31 with 39 UTR of SFRP4.
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